Related Experiment Video
Updated: Jun 24, 2026
09:52
Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
10.6K
[2023 update on alveolar echinococcosis]
Emeline Gauthiez1, Emilie Uldry2, Alix T Coste3
1Service de maladies infectieuses, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
Revue Medicale Suisse
|April 14, 2023
Summary
Alveolar echinococcosis, a severe parasitic infection, is rising in Europe, particularly in Switzerland. Early diagnosis and treatment are crucial for managing this complex hepatic disease, especially in immunocompromised individuals.
Area of Science:
- Parasitology
- Infectious Diseases
- Hepatology
Context:
- Alveolar echinococcosis is a severe parasitic disease with increasing prevalence in Europe, especially Switzerland.
- It presents a growing challenge in both urban and rural settings.
- The infection is increasingly observed in immunocompromised patients, complicating diagnosis due to atypical presentations.
Purpose:
- To highlight the rising prevalence and diagnostic challenges of alveolar echinococcosis.
- To emphasize its importance as a differential diagnosis for hepatic lesions.
- To underscore the need for awareness, particularly in immunocompromised populations.
Summary:
- Alveolar echinococcosis is a significant cause of morbidity and mortality in Europe, with increasing incidence in Switzerland.
- Cystic hepatic lesions warrant consideration of echinococcosis as a differential diagnosis.
- The disease poses diagnostic complexities in immunocompromised patients due to atypical and rapidly evolving lesions.
Impact:
- Increased awareness can lead to earlier diagnosis and intervention for alveolar echinococcosis.
- Understanding the diagnostic challenges aids clinicians in managing complex cases.
- Effective surgical and medical treatments offer a good prognosis and improved quality of life for affected patients.
Related Concept Videos
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:28Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
01:22American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
01:28Amebiasis
Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...